The Big Unlock
Episode 222 – AI is Moving Drug Discovery From Prediction to Generation
The Big Unlock · Alex Zhavoronkov, Founder, CEO and CBO, Insilico Medicine In this episode, Alex Zhavoronkov, Founder, CEO and CBO of Insilico Medicine, explores how generative AI is reshaping drug discovery and opening new possibilities in longevity research. He explains how AI can move pharmaceutical R&D from searching for promising molecules toward generating molecules with desired properties, while orchestrating specialized models and agents across the drug development lifecycle. Insilico combines AI models across biology, chemistry, and clinical development to move from target identification to drug candidates faster, with multiple programs now in clinical trials. Alex argues that AI can dramatically expand the number of experiments researchers can conduct, but the complexity of biology means failure remains inevitable and real-world validation is essential. He discusses the industry’s shift from predictive AI to generative and agentic systems capable of orchestrating thousands of drug discovery tasks, while emphasizing the importance of rigorous validation. Alex believes the strongest competitive advantages will come from proprietary drugs, scientific infrastructure, capital, and the ability to turn ideas into validated products. He cautions against AI hype and emphasizes benchmarking, peer-reviewed evidence, and clinical results. His ultimate ambition is to use AI-driven drug discovery to extend human lifespan and give people more years of life. Take a listen. This guest appearance was facilitated through conversations initiated at Ai4 2026 .
